GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as ...

England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

The National Institute for Health and Care Excellence (NICE) has issued a draft guidance recommending GSK’s Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BVd) for ...

Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending approval for the Blenrep (belantamab mafodotin) combination therapy to treat relapsed or refractory ...

It has been dubbed a “Trojan horse” treatment because it works by being taken into a cancer cell, before releasing a high ...

A “TROJAN HORSE” therapy that sneaks toxic drugs inside and kills cancer cells is being rolled out on the NHS in England in a ...

Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of GSK’s Blenrep (belantamab mafodotin) for treating the adult population with relapsed or refractory multiple ...

Less than two years after pulling multiple myeloma therapy Blenrep off most markets around the world, GSK has filed for approval of the drug in the EU once again, hoping to restore its blockbuster ...

Dec 9 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple ...